Aducanumab Cost ....Yearly treatment cost was stated at around $50,000.00 U.S. dollar per year , so do the math for market share . Biogen's stock will explode in the future , so I wonder what Promis stock would do with FDA approval $70.00 a share in the future for a buyout , as Gene stated a couple years back most likely the whole company would be bought out , as he stated PMN310 would be in someone else's hand . So that's why I have hold for long term hopefully within 5 yrs. there will be a known direction .